Biological agents in head and neck cancer

Expert Review of Anticancer Therapy

Volumn 7, Issue 11, 2007, Pages 1643-1650

  Bossi, Paolo ^a   Locati, Laura D ^a   Licitra, Lisa ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Biological agents; Clinical trials; Head and neck cancer; Molecular basis

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; B RAF KINASE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; DACARBAZINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; GEFITINIB; IMATINIB; LAPATINIB; METHOTREXATE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PACLITAXEL; PLACEBO; PROTEIN P53; PROTEIN RET; SORAFENIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VIRUS DNA;

BIOLOGICAL THERAPY; BLEEDING; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DESQUAMATION; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG ERUPTION; DYSPHAGIA; EPSTEIN BARR VIRUS; FEBRILE NEUTROPENIA; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HUMAN; LARYNX CANCER; MEDICAL RESEARCH; METASTASIS POTENTIAL; MOLECULAR BIOLOGY; MONOTHERAPY; MUCOSA INFLAMMATION; NASOPHARYNX CANCER; OVERALL SURVIVAL; PROGNOSIS; RADIATION INJURY; REVIEW; SALIVARY GLAND CANCER; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE; THROMBOSIS; THYROID CANCER; TRACHEA CANCER; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR BLEEDING; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 37349077937     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.11.1643     Document Type: Review

References (94)

1. Temam S, Flahault A, Perie S et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J. Clin. Oncol. 18, 385-394 (2000).
2. Cabelguenne A, Blons H, de Waziers I et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J. Clin. Oncol. 18, 1465-1473 (2000).
3. Raybaud-Diogene H, Fortin A, Morency R et al. Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. J. Clin. Oncol. 15, 1038 (1997).
4. Couture C, Raybaud-Diogene H, Tetu B et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 94, 713-722 (2002).
5. Pomerantz RG, Grandis JR. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma. Curr. Oncol. Rep. 5, 140-146 (2003).
6. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol. Ther. 102, 37-46 (2004).
7. Grandis JR, Melhem MF, Gooding WE et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst. 90, 824-832 (1998).
8. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62, 7350-7356 (2002).
9. Eriksen JG, Steiniche T, Askaa J, Alsner J, Overgaard J. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 58, 561-566 (2004).
10. Bentzen SM, Atasoy BM, Daley FM et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J. Clin. Oncol. 23, 5560-5567 (2005).
11. Lee JW, Soung YH, Kim SY et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11, 2879-2882 (2005).
12. Freier K, Joos S, Flechtenmacher C et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res. 63, 1179-1182 (2003).
13. Mrhalova M, Plzak J, Betka J, Kodet R. Epidermal growth factor receptor - its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. Neoplasma 52, 338-343 (2005).
14. Gebhart E, Ries J, Wiltfang J, Liehr T, Efferth T. Genomic gain of the epidermal growth factor receptor harboring band 7p12 is part of a complex pattern of genomic imbalances in oral squamous cell carcinomas. Arch. Med. Res. 35, 385-394 (2004).
15. Chung CH, Ely K, McGavran L et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 24, 4170-4176 (2006).
16. Thomas SM, Bhola NE, Zhang Q et al. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res. 66, 11831-11839 (2006).
17. Rajput A, Koterba AP, Kreisberg JI et al. A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer Res. 67, 665-673 (2007).
18. Gallo O, Franchi A, Magnelli L et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3, 53-61 (2001).
19. Pore N, Jiang Z, Gupta A et al. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 66, 3197-3204 (2006).
20. Mineta H, Miura K, Ogino T et al. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br. J. Cancer 83, 775-781 (2000).
21. Koukourakis MI, Bentzen SM, Giatromanolaki A et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 α and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J. Clin. Oncol. 24, 727-735 (2006).
22. Sridhar SS, Hedley D. Siu LL. Raf kinase as a target for anticancer therapeutics. Mol. Cancer Ther. 4, 677-685 (2005).
23. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006).
24. Bonner JA, Harari PM, Giralt J et al. EGFR expression and clinical outcome in head and neck patients treated with radiotherapy with or without cetuximab. Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, June 2-6 2006.
25. Pfister DG, Su YB, Kraus DH et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot Phase II study of a new combined-modality paradigm. J. Clin. Oncol. 24, 1072-1078 (2006).
26. Merlano M, Numico G, Russi EG et al. Cetuximab (C-mab) and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): a Phase II study. Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, June 1-5 2007.
27. Kies MS, Garden AS, Holsinger C et al. Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN). Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, June 2-6 2006.
28. Doss HH, Greco FA, Meluch AA et al. Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/ gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: a Phase I/II trial of the Minnie Pearl Cancer Research Network. Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, June 2-6 2006.
29. Savvides P, Agarwala SS, Greskovich J et al. Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). Presented at: 42nd ASCO Annual Meeting. Atlanta, CA, USA, June 2-6 2006.
30. Herchenhorn D, Dias FL, Pineda RM et al. Phase II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, June 1-5 2007.
31. Ahmed SM, Cohen EE, Haraf DJ et al. Updated results of a Phase II trial integrating gefitinib (G) into concurrent chemoradiation (CRT) followed by G adjuvant therapy for locally advanced head and neck cancer (HNC). Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, June 1-5 2007.
32. Bourhis J, Harrington K, Rosine D et al. A Phase I, open-label study (EGF100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Ann. Oncol. 17(Suppl. 9) (2006).
33. Rueda A, Medina JA, Mesia R et al. Gefitinib plus concomitant boost accelerated radiation (AFX-CB) and concurrent weekly cisplatin for locally advanced unresectable squamous cell head and neck carcinomas (SCCHN): a Phase II study. Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, June 1-5 2007.
34. Prellop P, Peters G, Carroll W et al. Radiosensitization with a COX2 inhibitor with chemoradiation for head and neck cancer. Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, June 2-6 2006.
35. Seiwert TY, Haraf DJ, Cohen EE et al. A Phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC). Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, June 2-6 2006.
36. Savvides P, Greskovich J, Bokar J et al. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, June 1-5 2007.
37. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 23, 8646-8654 (2005).
38. Vermorken J, Mesia R, Vega V et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - Results of a randomized Phase III (Extreme) study Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, June 1-5 2007.
39. Hitt R, Irigoyen A, Nuñez J et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/ recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC). Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, June 1-5 2007.
40. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23, 5568-5577 (2005).
41. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23, 5578-5587 (2005).
42. Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 25, 2171-2177 (2007).
43. Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 21, 1980-1987 (2003).
44. Glisson B, Kim ES, Kies MS et al. Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin. Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, June 2-6 2006.
45. Cohen EE, Kane MA, List MA et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11, 8418-8424 (2005).
46. Stewart JS, Cohen EE, Licitra L et al. A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck. Presented at: AACR Annual Meeting. Los Angeles, CA, USA, April 14-18 2007.
47. Soulieres D, Senzer NN, Vokes EE et al. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22, 77-85 (2004).
48. Siu LL, Soulieres D, Chen EX et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital Phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J. Clin. Oncol. 25, 2178-2183 (2007).
49. Kim ES, Kies MS, Glisson BS et al. Final results of a Phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/ metastatic head and neck cancer. Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, June 1-5 2007.
50. Belón J, Irigoyen A, Rodríguez I et al. Preliminary results of a Phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Presented at: 41st ASCO Annual Meeting. Orlando, FL, USA, May 13-17 2005.
51. Wirth LJ, Haddad RI, Lindeman NI et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23, 6976-6981 (2005).
52. Vokes EE, Cohen EE, Mauer AM et al. A Phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). Presented at: 41st ASCO Annual Meeting. Orlando, FL, USA, May 13-17 2005.
53. Williamson SK, Moon J, Huang CH et al. A Phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): a Southwest Oncology Group (SWOG) trial. Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, June 2-6 2006.
54. Abidoye OO, Cohen EE, Wong SJ et al. Phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, June 2-6 2006.
55. Weber F, Xu Y, Zhang L et al. Microenvironmental genomic alterations and clinicopathological behavior in head and neck squamous cell carcinoma. JAMA 297, 187-195 (2007).
56. Yip KW, Shi W, Pintilie M et al. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin. Cancer Res. 12, 5726-5732 (2006).
57. Ma BB, Poon TC, To KF et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study. Head Neck 25, 864-872 (2003).
58. Chua DT, Nicholls JM, Sham JS, Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59, 11-20 (2004).
59. Agaoglu PY, Dizdar Y, Dogan O et al. p53 overexpression in nasopharyngeal carcinoma. In Vivo 18, 555-560 (2004).
60. Chan AT, Hsu MM, Goh BC et al. Multicenter, Phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J. Clin. Oncol. 23, 3568-3576 (2005).
61. Straathof KC, Bollard CM, Popat U et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105, 1898-1904 (2005).
62. Comoli P, Pedrazzoli P, Maccario R et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 23, 8942-8949 (2005).
63. Holst VA, Marshall CE, Moskaluk CA, Frierson HF Jr. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod. Pathol. 12, 956-960 (1999).
64. Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett. 154, 107-111 (2000).
65. Locati LD, Perrone F, Losa M et al. Treatment relevant immunophenotyping of 139 salivary gland carcinomas (SGCs). Ann. Oncol. (2007) (In Press).
66. Hotte SJ, Winquist EW, Lamont E et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital Phase II consortium study. J. Clin. Oncol. 23, 585-590 (2005).
67. Pfeffer MR, Talmi Y, Catane R et al. A Phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 43, 33-36 (2007).
68. Alcedo JC, Fabrega JM, Arosemena JR, Urrutia A. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck 26, 829-831 (2004).
69. Faivre S, Raymond E, Casiraghi O, Temam S, Berthaud P. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J. Clin. Oncol. 23, 6271-6273 (2005).
70. Glisson B, Colevas AD, Haddad R et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin. Cancer Res. 10, 944-946 (2004).
71. Haddad R, Colevas AD, Krane JF et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A Phase II study. Oral Oncol. 39, 724-727 (2003).
72. Glisson BS, Blumenschein G, Francisco M et al. Phase II trial of gefitinib in patients with incurable salivary gland cancer. Presented at: 41st ASCO Annual Meeting. Orlando, FL, USA, May 13-17 2005.
73. Licitra L, Locati LD, Potepan P et al. Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): A monoinstitutional Phase II study. Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, June 2-6 2006.
74. Agulnik M, Cohen EE, Cohen RB et al. A multicenter Phase II study of lapatinib in recurrent or metastatic adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). Ann. Oncol. 17(Suppl. 9), ix179 (2006).
75. Locati LD, Quattrone P, Bossi P et al. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann. Oncol. 14, 1327-1328 (2003).
76. van der Hoist RW, van Krieken JH, van der Kwast TH et al. Partial remission of parotid gland carcinoma after goserelin. Lancet 344, 817 (1994).
77. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J. Endocrinol. 183, 249-256 (2004).
78. Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G. Molecular mechanisms of RET activation in human cancer. Ann. NY Acad. Sci. 963, 116-121 (2002).
79. Xing M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12, 245-262 2005).
80. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
81. Nikiforova MN, Kimura ET, Gandhi M et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88, 5399-5404 (2003).
82. Xing M, Westra WH, Tufano RP et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90, 6373-6379 (2005).
83. Melillo RM, Castellone MD, Guarino V et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 115, 1068-1081 (2005).
84. Soh EY, Duh QY, Sobhi SA et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J. Clin. Endocrinol. Metabol. 82, 3741-3747 (1997).
85. Wiseman SM, Masoudi H, Niblock P et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann. Surg. Oncol. 14, 719-729 (2007).
86. Lee DH, Lee GK, Kong SY et al. Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J. Clin. Pathol. 60, 881-884 (2007).
87. Argiris A, Goldwasser MA, Burtness B et al. A Phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: an Eastern Cooperative Oncology Group study. Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, June 2-6 2006.
88. Zonnenberg BA, Links T, Quarles van Uffort P et al. Phase-2 study of imatinib in metastasized medullary thyroid carcinoma. Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, June 2-6 2006.
89. Hoff PM, Hoff AO, Phan A et al. Phase I/II trial of capecitabine (C), dacarbazine (D) and imatinib (I) (CDI) for patients (pts) metastatic medullary thyroid cancer (MTC). Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, June 2-6 2006.
90. Sherman SI, Schlumberger MJ, Droz J et al. Initial results from a Phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, June 1-5 2007.
91. Kloos R, Ringel M, Knopp M et al. Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): updated results of a Phase II study. Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA, June 2-6 2006.
92. Wells SA, Gosnell JE, Gagei RF et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label Phase II trial. Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, June 1-5 2007.
93. Pennell NA, Daniels GH, Haddad RI et al. A Phase II study of gefitinib in patients with advanced thyroid cancer. Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, June 1-5 2007.
94. Cohen EE, Vokes EE, Rosen LS et al. A Phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers. Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, June 1-5 2007.